Pulmonx outlines 2026 revenue target of $90M-$92M with cost realignment and renewed U.S. sales focus (NASDAQ:LUNG)

Pulmonx (LUNG) Q4 2025 earnings call recap: 2026 revenue guidance, cost cuts, sales force reset, and AeriSeal trial update—get key takeaways now.

You are being redirected to the original discussion. Please continue if you want to read the full post.

You will be redirected in 3 seconds.